Stock Ticker

  • Loading stock data...

Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG)

Amgen Inc. (NASDAQ:AMGN) has announced the purchase of Celgene Corporation’s (NASDAQ:CELG) leading immunology drug Otezla for around $13.4 billion. Otezla purchase deal to be finalized at the end of the year The company has indicated that the deal will be closed at the end of the year. Following the announcement, Amgen’s stock gained 2.85% to […]

Amgen, Inc. (NASDAQ:AMGN) And Array Biopharma Inc (NASDAQ:ARRY) Partners For Inflammation Discoveries

Amgen, Inc. (NASDAQ:AMGN) and Array Biopharma Inc (NASDAQ:ARRAY) have announced today the partnership agreement as an effort to discover and develop new drugs for autoimmune diseases. The unrevealed target and lead inhibitors were found out through the Array’s proprietary podium that leverages its capability in chemistry and early development. Array Biopharma made a deal with […]

Advaxis, Inc. (NASDAQ:ADXS) Gets IND Acceptance From The Food And Drug Administration For ADXS-NEO

Advaxis, Inc. (NASDAQ:ADXS) has revealed that the Food and Drug Administration of the United States has given the go-ahead for an application filed to try out ADXS-NEO. Development of the treatment is being done in partnership with Amgen, Inc. (NASDAQ:AMGN). “The IND acceptance is a landmark step towards escaping the one-size-fits-all approach to cancer treatments […]

Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab

Boston, MA 10/03/2014 (wallstreetpr) – Amgen, Inc. (NASDAQ:AMGN) disclosed that the Lancet published data from two Stage three trials, TESLA and RUTHERFORD-2. The data pointed out that the treatment with novel investigational low-density lipoprotein cholesterol or LDL-C, evolocumab, resulted in a statistically important reduction in LDL-C. The data compared with the placebo in patients affected […]

Amgen, Inc. (NASDAQ:AMGN)’s Chronic Heart Failure Drug Receives Priority Designation From FDA

Boston, MA 08/28/2014 (wallstreetpr) – The U.S. biotechnology company Amgen, Inc. (NASDAQ:AMGN) declared in its press report that it had received a green signal from the U.S. Food and Drug Administration (FDA) for the priority review designation for ‘ivabradine.’ The effectiveness of the oral drug Ivabradine: Ivabradine is an oral drug used for the treatment […]

Amgen, Inc. (NASDAQ:AMGN)’S Clinical Trials On Talimogene Laherparepvec Show Significant Response Rate

Boston, MA 06/05/2014 (wallstreetpr) – Amgen, Inc. (NASDAQ:AMGN) presented findings from two clinical trials on Talimogene laherparepvec at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago. The two clinical trials with the drug, which is a novel investigational drug employed in oncolytic immunotherapy involved evaluating the […]

Sign Up To Get Our Latest Stocks Alerts